Technical Analysis for ONCT - Oncternal Therapeutics, Inc.

Grade Last Price % Change Price Change
F 5.2 0.19% 0.01
ONCT closed up 0.19 percent on Wednesday, June 23, 2021, on 49 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical ONCT trend table...

Date Alert Name Type % Chg
Bollinger Band Squeeze Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
BB Squeeze + Lower Band Touch Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Lower Bollinger Band Touch Weakness 0.00%
20 DMA Resistance Bearish 0.19%
Bollinger Band Squeeze Range Contraction 0.19%
BB Squeeze + Lower Band Touch Range Contraction 0.19%
Lower Bollinger Band Touch Weakness 0.19%
Older End-of-Day Signals for ONCT ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible Inside Day about 16 hours ago
Possible NR7 about 16 hours ago
60 Minute Opening Range Breakdown about 18 hours ago
Down 1% about 19 hours ago
Up 1% about 20 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Oncternal Therapeutics, Inc. Description

Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on developing a diverse pipeline of product candidates for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer progression. The pipeline includes cirmtuzumab, a monoclonal antibody designed to inhibit the ROR1 receptor that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of CLL and MCL, and TK-216, a small-molecule compound that is designed to inhibit ETS-family oncoproteins, which is being evaluated in a Phase 1 clinical trial alone and in combination with vincristine as a treatment for Ewing sarcoma, a rare pediatric cancer. In addition, Oncternal has a CAR-T product candidate that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Development Solid Tumors Treatment Of Cancer Cancers Chemical Compounds Monoclonal Antibody Organic Compounds Drug Development Sarcoma Treatment Of Cancers Hematologic Cancers

Is ONCT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 10.55
52 Week Low 1.49
Average Volume 1,090,263
200-Day Moving Average 4.95
50-Day Moving Average 5.67
20-Day Moving Average 5.44
10-Day Moving Average 5.34
Average True Range 0.35
ADX 10.69
+DI 15.05
-DI 18.88
Chandelier Exit (Long, 3 ATRs) 4.82
Chandelier Exit (Short, 3 ATRs) 6.04
Upper Bollinger Bands 5.75
Lower Bollinger Band 5.12
Percent B (%b) 0.12
BandWidth 11.62
MACD Line -0.13
MACD Signal Line -0.14
MACD Histogram 0.0086
Fundamentals Value
Market Cap 116.2 Million
Num Shares 22.3 Million
EPS -1.81
Price-to-Earnings (P/E) Ratio -2.87
Price-to-Sales 17.77
Price-to-Book 3.80
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.46
Resistance 3 (R3) 5.46 5.37 5.41
Resistance 2 (R2) 5.37 5.31 5.37 5.40
Resistance 1 (R1) 5.29 5.27 5.25 5.29 5.38
Pivot Point 5.20 5.20 5.18 5.20 5.20
Support 1 (S1) 5.12 5.14 5.08 5.12 5.02
Support 2 (S2) 5.03 5.10 5.03 5.00
Support 3 (S3) 4.95 5.03 4.99
Support 4 (S4) 4.95